Daklinza(daclatasvir)
Daklinza (daclatasvir) is a small molecule pharmaceutical. Daclatasvir was first approved as Daklinza on 2014-08-22. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Daclatasvir dihydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DAKLINZA | Bristol Myers Squibb | N-206843 DISCN | 2015-07-24 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
| hepatitis c | — | D006526 | B19.2 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
123 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | B19.2 | 8 | 9 | 20 | 6 | 8 | 50 | |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 4 | 15 | 8 | 2 | 5 | 29 |
| Covid-19 | D000086382 | U07.1 | — | 6 | 5 | 1 | — | 8 | |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | 1 | 1 | 3 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | 1 | 1 | — | 3 |
| Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepacivirus | D016174 | — | 6 | 4 | — | — | 10 | ||
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | — | 2 | 4 | — | 1 | 5 |
| Hepatitis b | D006509 | — | 2 | 3 | — | — | 5 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 1 | 1 | — | 2 | 4 |
| Hiv | D006678 | O98.7 | 1 | — | 1 | — | — | 2 | |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 1 | 1 | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | 1 | 1 | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | 1 | — | — | 1 |
| Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | 2 | — | — | — | — | 2 | ||
| Hepatic insufficiency | D048550 | 2 | — | — | — | — | 2 | ||
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fibrosis | D005355 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DACLATASVIR |
| INN | daclatasvir |
| Description | Daclatasvir is a member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C. It has a role as a nonstructural protein 5A inhibitor and an antiviral drug. It is a member of biphenyls, a member of imidazoles, a carbamate ester, a carboxamide and a valine derivative. It is a conjugate base of a daclatasvir(2+). |
| Classification | Small molecule |
| Drug class | antivirals: nonstructural protein 5A (NS5A) inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 1009119-64-5 |
| RxCUI | 1606218 |
| ChEMBL ID | CHEMBL2023898 |
| ChEBI ID | 82977 |
| PubChem CID | 25154714 |
| DrugBank | DB09102 |
| UNII ID | LI2427F9CI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Daklinza - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,820 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
74,389 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more